Specifying an In Vivo Comet Assay for a RAS(ON) Multi-Selective Inhibitor Candidate: A Request-for-Proposal Framework for Genotoxicity Studies Supporting FDA IND Submission
A request for proposal (RFP) for a nonclinical study must give a contract research organization (CRO) enough scientific and regulatory detail to design the study correctly and to price it accurately on the first attempt. This article builds such an RFP for the in vivo alkaline comet assay, a supplementary component of a genotoxicity battery, for a hypothetical oral RAS(ON) multi-selective inhibitor candidate. The rationale is class-level: a tri-complex mechanism that suppresses proliferative and DNA damage response signalling, an intended chronic oncology exposure, and the weight-of-evidence logic of ICH S2(R1) together justify tissue-level DNA strand break data beyond the standard in vitro and bone marrow micronucleus assays. The RFP specifies species, tissues, dose selection, toxicokinetic confirmation, endpoints, statistics, deliverables, a 14-week schedule, an itemized budget of USD 57,000 to 86,000, vendor qualification criteria, and regulatory standards. The article closes with recommendations for strengthening the RFP and for avoiding confidentiality, intellectual property, and copyright exposure in vendor relationships.Keywords: request for proposal; genotoxicity; in vivo comet assay; OECD Test Guideline 489; ICH S2(R1); FDA IND; GLP; CRO selection
Authors
- Avinash Dundigalla
- Daxaben Jigneshkumar Patel
- Afeefa Mahmood
- Kritica
- Peivand Pirouzi
Institutions
- Northeastern University (US)
Publication Details
- Journal
- Zenodo (CERN European Organization for Nuclear Research)
- Published
- 2026-11-21
- DOI
- https://doi.org/10.5281/zenodo.24425099
- Primary Topic
- Carcinogens and Genotoxicity Assessment
- Type
- article
- Field-Weighted Citation Impact
- 0.00